Skip to main
LFST

LFST Stock Forecast & Price Target

LFST Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LifeStance Health Gr is in an advantageous position in the mental healthcare industry due to its unique hybrid model and strong financials. With a high percentage of revenue from Commercial plans, the company is able to generate higher rates and has lower exposure to government payers. However, competition from other health-tech companies and potential risks such as changes in laws and regulations, and technological advancements should also be considered in its outlook. Despite these challenges, LFST is expected to experience long-term revenue growth and has a strong management team focused on quality care and business strategy, making it a top pick in the sector.

Bears say

LifeStance Health Gr is facing competition from a number of other health-tech companies that focus on mental health, including Talkspace(TALK, Not Rated) and Teladoc's BetterHelp (TDOC, Neutral), general tele-health companies, including Amwell (AMWL, Neutral)and LifeMD (LFMD, Buy, $10 PT) and a significant exposure to reimbursement rates and the possibility of rate declines can lead to a headwind for LFST. Additionally, the company relies heavily on third-party suppliers, making it vulnerable to disruption and the high EV / 12.6x 2027E EBITDA multiple is concerning given the average multiple for its subsector being just 8.9x.

LFST has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeStance Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeStance Health Group (LFST) Forecast

Analysts have given LFST a Buy based on their latest research and market trends.

According to 7 analysts, LFST has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeStance Health Group (LFST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.